The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Oral prednisone 1might be a convenient, inexpensive alternative to IV methylprednisolone (IVMP) if the bioequivalent dose was known. We compared the total amount of steroid absorbed after 1250 mg oral prednisone vs 1 gram IVMP in 16 patients with multiple sclerosis (MS). At 24 hours, the mean area under the concentration-time curve (AUC), the main component of bioavailability, did not differ between groups (p = 0.122). This suggests that the amount of absorbed corticosteroid is similar after either steroid at these doses.
- Received April 7, 2004.
- Accepted in final form June 9, 2004.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
- Reply to Strupp
- Luanne M Metz, University of Calgary, 12th Floor Neurosciences, Foothills Medical Centre, 1403-29th Street NW, Calgary, AB, T2N 2T9lmetz@ucalgary.ca
Submitted November 18, 2004 - The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis
- Michael Strupp, Department of Neurology at the University of Munich, Klinikum Grosshadern, Marchioninistrasse 15, D-81377 Munich, GermanyMstrupp@nefo.med.uni-muenchen.de
Submitted November 18, 2004
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Fabricio Ferreira de Oliveira and Dr. Alan Cronemberger Andrade
► Watch
Related Articles
Alert Me
Recommended articles
-
In This Issue
September 28 Highlight and Commentaryet al.Neurology, September 27, 2004 -
Articles
Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MSF. Sellebjerg, J. L. Frederiksen, P. M. Nielsen et al.Neurology, August 01, 1998 -
Article
Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?Hadas Stiebel-Kalish, Mark Andrew Hellmann, Michael Mimouni et al.Neurology: Neuroimmunology & Neuroinflammation, May 21, 2019 -
Articles
A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritisF. Sellebjerg, H. Schaldemose Nielsen, J.L. Frederiksen et al.Neurology, April 01, 1999